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Immunogens and Antigen Processing: Report from a 
Global HIV Vaccine Enterprise Working Group
John Mascola, C Richter King & Ralph Steinman on behalf of a Working Group convened by the Global HIV 
Vaccine Enterprise
The Global HIV Vaccine Enterprise  (the Enterprise) convened a 
meeting of a Working Group in July 2009 to discuss recent progress 
in rational design of the components of an HIV vaccine, such as 
inserts, vectors and adjuvants, and in understanding antigen pro-
cessing and presentation to T and B cells. This Report summarizes 
the key points of that discussion, and subsequent discussions with 
the Chairs of the other Enterprise Working Groups, the Enterprise 
Science Committee, the Enterprise Council and the broader scientific 
community during open sessions at scientific conferences.
A. IntroductIon
An effective HIV vaccine will need to induce durable immune 
responses that prevent the acquisition of infection and/or reduce 
viral replication to levels necessary to minimize HIV disease and 
viral transmission1–4. Designing an immunogen capable of eliciting 
and maintaining such immune responses remains a major obstacle 
to the development of an HIV vaccine2,5–7. Experiments in non-
human primate (NHP) models have demonstrated that neutralizing 
antibodies are able to prevent infection8–11 and that cellular immune 
responses can control viral replication2,12–14. However, the immune 
correlates of protection against HIV in humans are not known4,15. 
The findings of the RV144 vaccine trial suggest that vaccine-elicited 
immune responses can decrease the acquisition rate of HIV16. Further 
analysis of this trial is currently underway and it is not yet clear if 
immune correlates of protection will emerge17. A better understand-
ing of protective immune responses, coupled with an improved abil-
ity to induce robust anti-HIV responses by immunization, are key to 
future success in the design and testing of HIV vaccines. We need to 
improve our mechanistic understanding of the intertwined functions 
of T-cells, B-cells, dendritic cells and other innate immune elements 
in controlling adaptive immunity18–20. In parallel, we need to learn 
how different vaccine platforms can induce protective responses and 
engender long-term effector populations by the different arms of the 
immune system. Studies of vaccine immunogenicity and efficacy in 
humans are essential to understand immune responses and to estab-
lish immune correlates of vaccine-induced protection. We propose 
that the Enterprise vigorously support a new era of HIV vaccine 
research and development in which discovery science is the engine 
driving our efforts to identify protective mechanisms and create new 
vaccine immunogens and immunization strategies.
This new era of vaccine science will require a programmatic mix 
that recognizes the complementary and distinct roles of individual 
scientists and multidisciplinary groups of researchers focusing on 
problems that require collaborative efforts. Teams are especially 
important in clinical trials, where a wide ranging set of skills is 
required. Knowledge gained from carefully conducted immunoge-
nicity and protection studies in non-human primates is also essential 
to provide fundamental scientific insights and influence the design 
of human clinical trials.
B. ScIentIfIc PrIorItIeS
The Working Group identified key scientific gaps in immunology, 
virology and vaccine design. Addressing these gaps presents an 
opportunity to significantly advance our understanding of vaccine 
science and accelerate the path to a safe and effective HIV vaccine. 
These scientific gaps were encompassed into three main priorities.
Priority 1: Study immune mechanisms of protection against 
HIV infection and disease progression
Factors contributing to the development of neutralizing antibodies. 
Recent studies have shown that 10–25% of HIV- infected individuals 
generate broadly cross-reactive neutralizing antibodies against HIV 
(bNAbs)21,22. While such NAbs may appear too late during infection 
to play a protective role, data from NHP studies8,23 show that bNAbs 
present before virus exposure protect against infection, suggesting 
that bNAbs might also prevent HIV infection in humans if present 
at the right time. Current vaccine immunogens generate low levels of 
NAbs that are reactive with a narrow subset of HIV strains. It is thus 
imperative to: (i) understand the evolution of the bNAb response 
during HIV infection; (ii) identify viral epitopes targeted by these 
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Priority 2: explore pathways to eliciting protective responses 
through vaccination
Structure-based design to improve B-cell immunogens. Well 
defined clinical cohorts provide the opportunity to derive new bNAbs 
against HIV. Examples of such antibodies include those known to 
neutralize via binding to gp41 (2F5, 4E10), to the CD4 binding site 
of gp120 (b12, VRC01) and those that bind to quaternary epitopes 
present on mature viral Env (PG9 and PG16)3,5,7,29,30. These anti-
bodies define conserved viral epitopes that could serve as the basis 
for improved immunogen design. A systematic effort using comple-
mentary methodologies to clone numerous NAbs from B-cells of 
humans infected with HIV, including non-clade B strains, would 
provide a better understanding of the nature of the bNAb response. 
Isolation of Nabs should be coupled with systematic efforts to define 
the atomic level structure of targeted viral epitopes and the inte-
gration of structural data with computational modeling to develop 
strategies for translating neutralization epitope data into vaccine 
immunogen design. The overall effort should be linked with efforts 
related to iterative immunogenicity testing of novel immunogens and 
with development of improved SHIV models.
Understand and modulate the B-cell response to overcome current 
limitations of vaccine immunogens and vaccination strategies, and 
better elicit protective antibodies. During HIV infection, there is a 
dominant type-specific NAb response to the autologous virus during 
the first months to years of infection; broadly reactive NAbs generally 
do not arise until 1-3 years of ongoing infection3. Similarly, vaccina-
tion with most Env immunogens results in dominant responses to 
some Env regions, such as the variable loops, that are poorly neutral-
izing and minimal responses to potential neutralization regions such 
as the CD4bs or the membrane-proximal external region. The mech-
anistic explanation for the poor immune responses to key regions of 
Env during natural infection and after primary immunization should 
be a major focus of study.
While it is appropriate to focus on the design of improved vaccine 
immunogens, it is likely that the method of antigen delivery and 
associated innate pathways engaged by immunization will impact 
the type, potency or breadth of NAb response elicited by a vaccine. 
For example, it may be possible to elicit NAbs to specific epitopes 
by modulating the method of antigen delivery or by stimulation of 
specific innate pathways. Studies in this area seek to understand: 1) 
why antigens reactive with bNAb don’t generate bNAbs when used as 
immunogens; 2) the impact of multimeric immunogens on the B-cell 
response; 3) the mechanism of immunodominance in the evolution 
of the natural NAb response and how it impacts the vaccine-elicited 
NAb responses. These studies are high-risk, and, thus, require teams 
of investigators with necessary expertise and funding schemes that 
support the scientific considerations.
Define pathways for vaccines to induce protective T-cells. There 
has been insufficient attention to the basic immunobiology of vac-
cination, i.e. how best to initiate and direct appropriate responses 
for the control of HIV. The data on mechanisms and correlates 
of protection will inform vaccine design. In addition, we need to 
understand how to elicit and direct protective adaptive immunity. 
Therefore, at the same time that information on immune correlates 
is being generated, a central focus should be the innate immune 
system, especially cells that capture and present vaccine antigens 
and dictate the quality and memory of the immune response. Briefly, 
immunization requires antigen/vaccine capture and presentation, 
especially by dendritic cells and follicular dendritic cells, to T and 
B cells, followed by differentiation of the latter into protective cells. 
Dendritic cell science has been underutilized in vaccine design, but 
antibodies; and (iii) learn how to elicit bNABs more efficiently (dis-
cussed in Priority 2). The first question is best studied in longitudinal 
HIV seroconversion cohorts, where time of HIV infection can be 
established and evolution of the antibody response can be tracked, 
including the roles of antibody affinity maturation, T-cell help, and 
genetics of virus and the host.
Need for robust animal models to study the in vivo role of HIV 
specific antibodies. NHP models can provide key information about 
the role of antibodies in protection against HIV. Monkey challenges 
with chimeric simian-human immunodeficiency viruses (SHIVs) 
allow the evaluation of HIV-specific antibody responses. However, 
the SHIV model is currently limited by the small number of biologi-
cally relevant viral strains that use the CCR5 co-receptor. Several 
of the currently used SHIVs do not cause persistent infection and 
induction of AIDS-like disease8–11. In addition, the SHIV model 
doesn’t address the challenge of viral diversity in humans since only 
a narrow panel of strains is available. Thus, replication-competent 
SHIVs from several major genetic subtypes should be constructed in 
order to study the role of antibodies against diverse viral strains. The 
generation of polyclonal SHIV stocks consisting of “swarms” of virus 
would also be valuable to better mimic human-to-human transmis-
sion. One strategy to improve the NHP model would be to generate 
altered forms of HIV resistant to host restriction factors present in 
monkeys cells, and, therefore, capable of infection and replication in 
NHPs. In addition to NHP studies, there was considerable discussion 
about proof of concept studies in humans to demonstrate the role 
of antibodies in protection against HIV-1 infection. Such passive 
antibody studies could provide key information about the character 
and level of protective antibodies in vivo.
CD8+ and CD4+ protective T-cell responses. There is accumulating 
evidence in both humans and NHPs of a protective role for CD8+ T 
cells in the control of HIV/SIV infection13,24–28. It is critical to define 
a metric to identify optimal types of CD8+ T cell responses required 
for protection. At the same time, a possible role for CD4+ T cells has 
been relatively neglected in the search for protective mechanisms and 
their precise roles in orchestrating the immune response against HIV 
has not been elucidated. CD4+ T cells have many potential roles in 
protection, from providing help to B and CD8+ T cells to directly 
killing MHC II+ HIV-infected T cells.
Studies of NHP challenge models and human elite controllers are 
essential to understand the role of antigen-specific T-cells in con-
ferring protection. By using systems biology approaches it is now 
feasible to study antigen-specific T cells elicited by different vac-
cines using small volumes of blood. Reliable ex vivo assays of T-cell-
mediated protection, in which T cells recognize naturally processed 
SIV and HIV antigens in infected CD4+ T cells, are needed. New 
technologies, for example, single cell assays, to detect the heterogene-
ity of T cell responses, are under development. Data on the full array 
of functional, antigen-specific CD4+ T cell populations [Treg, Th1, 
Th2, Th17] during vaccination and infection are needed and will 
greatly benefit from development of MHC II tetramers. All of these 
approaches will depend on strategies for the deposition, access and 
analysis of large amounts of data.
Another major question is whether the breadth of T cell response, 
i.e. the number of recognized HIV peptides, will be critical for vac-
cine efficacy. In addition, we need to investigate the feasibility of 
directing immune responses to specific T-cell epitopes, which cannot 
easily undergo mutation due to significant fitness cost to the virus. 
The role of select MHC alleles that mediate long-term control of 
viral load and disease progression in NHPs and humans also needs 
to be explored.
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Recent advances have elucidated a number of principles that make 
it feasible to reconsider the potential value of protein vaccines. To 
develop proteins for immune priming and/or repeated boosting, pro-
tein capture by dendritic cells must be optimized, together with the 
use of adjuvants appropriate to stimulate dendritic and other cells 
that will elicit protective T and B cell immunity.
Improve immune responses for vector-based vaccines. The use of 
vectors to deliver antigen-encoding genes is a leading strategy for 
the generation of an effective HIV vaccine32–34. The advantages of 
this approach include: exposure of the immune system to the antigen 
in a way that partially mimics a viral infection, flexibility of vector 
systems allowing control of their biological activity, track record of 
safety and immunogenicity of many vectors, proven methods for 
manufacture of many vectors for clinical trial, and ease of manip-
ulation of inserts in the vector to improve the immune response. 
Unfortunately, we have only limited understanding of the mecha-
nisms by which particular vectors/insert technologies induce an 
immunological response and the nature of the required stimulus for 
protection against HIV infection.
It is clear that alterations in vector change the responses to a given 
insert. Furthermore, the design of inserts for a specific vector can 
clearly direct the immune response to distinct T-cell and B-cell 
epitopes35,36. Consequently, there should be a close interplay between 
our understanding of the immunological mechanisms of protection 
as outlined in Priorities 1 and 2 and the development of both vec-
tors and inserts. Important parameters to be investigated include 
the study of vector tropism and mode of delivery, the impact of vec-
tor replication and persistence, and the importance of anti-vector 
immune responses. New designs of insert genes should be explored, 
especially those that allow for increased breadth of T-cell responses, 
the control of epitope-specific responses and the elicitation of bNAbs. 
The path forward will require detailed testing of new and existing 
vector/insert combinations, identification of improved methods for 
evaluating vector performance, and judicious use of NHP models 
and clinical trials to both advance existing candidates and inform 
design of succeeding generations of vaccines.
Compare performance properties of vector-based vaccines. A key 
challenge to the field is the large array of vector/insert combinations. 
Without an understanding of the underlying biological mechanisms 
that determine the immunological behavior of different vector/insert 
combinations, and in the absence of broadly agreed upon methods of 
assessment, the field is at great risk of spending considerable scarce 
resources on the generation of data which is not comparable and 
therefore does not allow for the advancement of the most promising 
candidates.
A harmonized and standardized set of assays is needed to allow 
comparison of vaccine performance in both NHPs and humans. An 
array of shared validated reagents, assays and methods is necessary 
to ensure that experiments conducted in different laboratories can be 
compared. Developers of vector/insert combinations and candidate 
vaccines should then be strongly encouraged to use these resources 
and publish data using these systems.
Where possible, clinical trials should be conducted that allow direct 
comparison of data obtained with different vector/insert technolo-
gies. The field has already implemented systems for standardization 
of immunological measurements obtained in human clinical testing 
allowing comparison across trials, and this should be continued and 
expanded. As data emerges on possible correlates of protection, the 
relevant assays should be validated and made widely available to 
facilitate comparisons.
dendritic cell function early on during vaccination serves to initiate 
and “imprint” T and B cell immunity (including in mucosa), control-
ling its quality and memory.
Understanding early events in immunization elicited by a variety 
of vectors, formulations and adjuvants will help uncover strategies 
to achieve protection. We need to learn what organs and cell types 
are accessed by vaccines and where immunogens are retained and 
presented. For example, information on the longevity of intact vac-
cine antigens on follicular dendritic cells and processed, presented 
antigens [peptide/MHC] on dendritic cells and their subsets, will be 
invaluable for vaccine design. An emphasis on early events also needs 
to include analyses of how adjuvants enhance immunity and control 
its quality. Advances in the science of pattern recognition receptors 
have provided major opportunities for rational adjuvant design, but 
the field needs to move beyond in vitro approaches in order to under-
stand the roles of these receptors as potential adjuvants to dendritic 
cells and other cells in vivo. Finally, NK cells also are potentially 
important modulators of dendritic cell activation.
Our ability to elicit protective immune responses depends on 
detailed understanding of the role of the mucosal immune system 
in protection against HIV. To induce protective T cells at defined 
mucosal sites, we should determine how different routes of mucosal 
delivery influence T cell generation. Following mucosal routes of 
immunization, a thorough assessment of the innate response should 
be performed at mucosal surfaces, including epithelial cells, NK cells, 
phagocytes and dendritic cells. Regardless of route, a fundamental 
parameter of the response is likely to be the ability of vaccines to 
improve effector T and B cell development in, or traffic to, mucosal 
sites. This will require data on the level of vaccine antigen and loca-
tion that leads to persistent T cell expansion without exhaustive sig-
nals. We need to learn how different prime-boost strategies and the 
timing of vaccine administration affect the quality of T cells. These 
areas of research should expand beyond model antigens in mice and 
focus on HIV/SIV antigens in humans/NHPs31.
This research requires better reagents (for example, monoclonal 
antibodies) and methods (for example, high resolution imaging tech-
niques to visualize vaccines and cells in vivo) to identify and isolate 
distinct types of immune cells in NHPs and humans. More effort 
is needed to learn how vaccines and adjuvants could be better for-
mulated and delivered. A mechanism for centralized manufacturing 
and distribution of key vaccine components (adjuvants, gene inserts, 
proteins) would accelerate the research and allow standardization 
and comparability of results.
In summary, we have made considerable progress in advancing 
our understanding of the immune response. We now need to build 
on this understanding and learn to direct, augment and speed up the 
response to relevant epitopes of the virus.
Priority 3: explore a diversity of vaccination strategies taking 
into account the need for comparability of data
Develop protein vaccines for priming and/or repeated boosting. 
Protein vaccines have been relatively neglected, with the exception 
of boosting with viral envelopes to elicit antibodies. This neglect 
logically stems from the insufficient immunogenicity of proteins 
observed previosuly3. On the other hand, proteins offer advantages 
in terms of lower manufacturing costs, ease of distribution, and 
smaller number of complications that arise through the use of vec-
tors (for example, prior immunity). Therefore, we should assess viral 
vector prime - protein boost vaccination strategies in parallel with 
protein-only approaches to reduce the effect of vector competition 
and preexisting immunity.
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c. StrAtegIc recommendAtIonS
In addition to the scientific priorities identified above, the Working 
Group put forward three strategic Recommendations to facilitate HIV 
vaccine research and development.
Focus NHP studies on understanding the immunological principles 
that underlie the induction of robust T- and B-cell responses to vaccine 
immunogens, on investigating immune mechanisms associated with 
protection from infection, and on early events responsible for control 
of viral replication
Studies of vaccine immunogens, antigen processing and resulting 
immune responses can be performed in NHPs without the expense 
and time delay associated with production of clinical-grade vaccine 
materials. In addition, the NHP model allows the intensive study of 
local, systemic and mucosal immune responses, which are difficult to 
study in humans. Moreover, viral challenge studies can be performed 
in NHPs to elucidate mechanisms of immune protection, especially 
those that contain the nidus of incoming virus immediately after 
infection14,37 and lead to the genetic bottleneck of the virus that has 
been documented in both humans and NHPs38,39. These studies can 
provide fundamental knowledge that is critical to drive the design 
of novel vaccine concepts and inform the more efficient design of 
human clinical trials (Table 1).
Explore in phase I human trials and longitudinal cohorts of HIV-1 infec-
tion, mechanisms of adaptive immune responses and their links with 
innate immunity
Clinical trials present unique opportunities to gather critical infor-
4 nature precedings
table 1.  examples of areas in which nHP studies have the  
best opportunity to contribute to HIV vaccine research and  
development.
• Identifying sites where vaccine antigens are retained and presented
• Development of improved markers for immune cells in lymphoid and 
mucosal tissues
• Use of in vivo imaging to study the induction of immune responses to 
vaccine antigens
• Studying mechanisms of adjuvant effect on T and B cell immunity
• Studying mechanisms to sustain effector cells at mucosal surfaces
• Discovering properties of T-cells ex vivo that are associated with control 
of viral replication in vivo
• Comparing ability of different vectors to present antigen and induce 
immunity
• Studying the influence of antigen structure on neutralizing antibody 
responses
• Describing evolution of B-cell responses, including affinity maturation
• Studying effects of passive transfer of neutralizing or non-neutralizing 
antibodies on protection
• Studying the relative contribution of neutralizing, ADCC and other 
Fc-mediated effector Ab functions in mediating protection
• Determining the level of Env-specific antibody required to impact acqui-
sition
• Studying whether polyclonal antibodies with low or moderate neutralizing 
activity can mediate protection
• Studying whether there are antibodies that mediate antibody-dependent 
cytotoxicity without cell-free virus neutralization, and what effect they 
have on acquisition and disease progression
• Measuring the relative contribution of IgG vs IgA antibodies at the 
mucosal surface
• Exploring whether antibodies work to block initial infection of mucosal 
target cells or impact later events of viral spread
mation about human immune responses to vaccines (Table 2). It is 
imperative that these opportunities are fully explored in each trial. 
In addition, there is much to be learned about the role of adaptive 
immune responses in controlling viral replication from studies of 
HIV infection. Effective T-cell responses and neutralizing antibodies 
develop in some HIV infected subjects, and if such responses could 
be induced by a vaccine before viral exposure, HIV infection might 
be prevented or fully controlled.
Encourage investigators from within and outside the field of HIV vac-
cines to form teams targeting fundamental immunological questions 
and exploring novel approaches to vaccine discovery
HIV vaccine research and development would benefit from a far 
greater interaction between those studying HIV vaccines and scien-
tists from outside the field of HIV research (Table 3). New funding 
mechanisms should be created to facilitate the entry and continued 
involvement of new investigators, and groups of investigators, in the 
field of HIV immunology and vaccine development.
table 2.  examples of areas of focus for research in humans.
• Exploring innate responses to adjuvants and vectors and their relationship 
with adaptive immunity
• Studying mechanisms of immune control of viral replication in long-term 
non-progressors
• Studying the role of T cell help in eliciting improved B and CD8+ T-cell 
immunity
• Studying strategies for mucosal immunization
• Exploring approaches to increase breadth of T-cell responses or to direct 
them to specific epitopes
• Establishing seroconversion cohorts to study evolution of antibody 
responses
• Isolating novel neutralizing and binding mAbs from HIV infected subjects
• Comparing diverse vectors and prime-boost approaches
• Studying basic B-cell biology: evolution of B-cell response to HIV and the 
role of affinity maturation
• Developing ex vivo assays to mimic human immune responses in artificial 
lymph nodes
table 3.  examples of areas of HIV vaccine research in which 
expertise from the fundamental human immunology might 
accelerate progress.
• Understanding evolution of B-cell response to HIV and the role of affinity 
maturation
• Isolating novel anti-envelope Abs using new technologies
• Applying structure-based immunogen design to elicit neutralizing and 
protective antibodies
• Studying the role of mobilization of Fc receptors in protection
• Exploring the role of select MHC alleles in NHP and humans in resisting 
SIV/HIV
• Studying the role of CD4+ helper T cells in resistance to SIV/HIV
• Investigating mechanisms to sustain effector cells at mucosal surfaces
• Developing strategies to improve dendritic cell capture of vaccines
• Overcoming tolerogenic dendritic cell pathways, especially at mucosal 
surfaces
• Developing ex vivo assays for human immune responses (for example, 
artificial lymph nodes)
• Learning to assess the immune system and adaptive response of new-
borns
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table 4.  Summary of priorities and recommendations
Priority 1. Study immune mechanisms of protection against HIV infection and disease progression
• Establish multidisciplinary teams to study the evolution of B-cell responses in longitudinal cohorts
• Develop NHP models to study the in vivo immune responses to vaccination and infection
• Explore the role of breadth of responses in mediating protection against HIV
Priority 2. explore pathways to eliciting protective responses through vaccination
• Use structure-based design to improve B-cell immunogens
• Study the differences in immune responses to vaccines associated with different methods of antigen delivery
• Focus on the innate immune system, especially on cells that capture and present vaccine antigens dictating the quality of the immune response
• Focus on delivering vaccines to mucosal surfaces and measuring mucosal immune responses
• Encourage standardization by developing and making available vaccine components (proteins, inserts, adjuvants, etc.)
Priority 3. explore a diversity of vaccination strategies taking into account the need for comparability of data
• Develop protein vaccines for priming and/or repeated boosting
• Improve the immune responses for vector-based vaccines
• Compare performance properties of vector-based vaccines
Strategic recommendations
• Focus NHP studies on understanding the immunological principles that underlie the induction of robust T- and B-cell responses to vaccine immunogens, on 
investigating immune mechanisms associated with protection from infection, and on early events responsible for control of viral replication.
• Explore in phase I human trials and longitudinal cohorts, mechanisms of adaptive immune responses and their links with innate immunity.
• Encourage investigators from within and outside the field of HIV vaccines to form teams targeting fundamental immunological questions and exploring novel 
approaches to vaccine discovery.
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